$103.4 M

IPIX Mkt cap, 31-Oct-2017
Innovation Pharmaceuticals Net income (Q3, 2018)-11.5 M
Innovation Pharmaceuticals EBIT (Q3, 2018)-11.3 M
Innovation Pharmaceuticals Cash, 31-Mar-20181.3 M

Innovation Pharmaceuticals Financials

Innovation Pharmaceuticals Income Statement

Annual

USDFY, 2016

R&D expense

9 m

General and administrative expense

1.9 m

Operating expense total

10.9 m

EBIT

(12.7 m)

Interest expense

202 k

Interest income

4 k

Pre tax profit

(12.9 m)

Net Income

(12.9 m)

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q3, 2018

R&D expense

1.9 m2.3 m1.8 m2.1 m3 m2.3 m2.7 m3.2 m9.5 m

General and administrative expense

244 k275 k339 k352 k249 k362 k344 k331 k889 k

Operating expense total

2.2 m2.6 m2.2 m2.5 m3.3 m2.6 m3 m3.5 m11.4 m

EBIT

(2.7 m)(2.8 m)(2.5 m)(3.3 m)(3.7 m)(3 m)(3.3 m)(3.9 m)(11.4 m)

Interest expense

51 k51 k51 k50 k51 k51 k50 k51 k152 k

Interest income

1 k1 k1 k1 k1 k1 k1 k1 k

Pre tax profit

(2.8 m)(2.9 m)(2.6 m)(3.3 m)(3.7 m)(3 m)(3.4 m)(3.9 m)(11.5 m)

Net Income

(2.8 m)(2.9 m)(2.6 m)(3.3 m)(3.7 m)(3 m)(3.4 m)(3.9 m)(11.5 m)

Innovation Pharmaceuticals Balance Sheet

Annual

USDFY, 2016

Cash

6.3 m

Current Assets

6.7 m

Total Assets

11.4 m

Accounts Payable

42.2 m

Current Liabilities

8.5 m

Total Liabilities

8.5 m

Additional Paid-in Capital

57 m

Retained Earnings

(54 m)

Total Equity

3 m

Financial Leverage

3.9 x

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q3, 2018

Cash

7.1 m9.5 m10.8 m7.8 m6.2 m5.3 m1.3 m

Current Assets

7.2 m9.6 m11.4 m8 m6.4 m5.8 m1.5 m

Total Assets

12.5 m14.9 m17.1 m13.5 m11.9 m11.3 m5.8 m

Current Liabilities

8 m7.7 m7.3 m7.5 m7.6 m8.4 m9.5 m

Total Liabilities

9.5 m

Additional Paid-in Capital

36.9 m42.3 m47.8 m49.8 m51.3 m53.6 m77.3 m

Retained Earnings

(32.4 m)(35.2 m)(38.1 m)(43.7 m)(47.1 m)(50.8 m)(81.1 m)

Total Equity

4.5 m7.1 m9.8 m6 m4.3 m2.9 m(3.7 m)

Financial Leverage

2.8 x2.1 x1.7 x2.2 x2.8 x3.9 x-1.5 x

Innovation Pharmaceuticals Cash Flow

Annual

USDFY, 2016

Net Income

(12.9 m)

Accounts Payable

1.7 m

Cash From Operating Activities

(9.9 m)

Purchases of PP&E

(68 k)

Cash From Investing Activities

(414 k)

Cash From Financing Activities

8.2 m

Interest Paid

235 k

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(2.8 m)(2.9 m)(2.6 m)(3.3 m)(3.7 m)(3 m)(3.4 m)(3.9 m)

Innovation Pharmaceuticals Ratios

USDY, 2018

Financial Leverage

-1.5 x
Report incorrect company information